...
首页> 外文期刊>Transplant international : >Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
【24h】

Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.

机译:包括抗胸腺细胞球蛋白在内的诱导疗法可在肝移植后诱导T淋巴细胞亚群的显着变化:一项长期研究的结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Various immunosuppressive regimens aim to reduce the incidence of acute rejection after liver transplantation. The efficacy of antithymocyte globulin (ATG) induction therapy and short-term effects on the cellular response have been demonstrated in several studies. Nevertheless, information about long-term effects of ATG therapy on cellular responses and frequency of complications is limited. Therefore, we analyzed the effect of ATG administration within a cyclosporine-based induction therapy, including azathioprine and prednisolone, on lymphocyte subsets and activation markers. We divided 35 liver transplant recipients into two groups according to their initial postoperative immunosuppression: a triple group without ( n=15) and a quadruple group with ATG ( n=20). The minimum observation time (flow cytometry analysis, clinical follow-up) was 2 years. Patients treated with ATG had persistently lower percentages of T cells for at least 2 years postoperatively ( P<0.001). The CD4/CD8 ratios were lower in the quadruple group ( P<0.005). The patients in the ATG group revealed a drop in CD25(+) T cells within 2 years ( P<0.05). However, the percentage of CD71(+) and HLA-DR(+) T cells was temporarily higher in patients with ATG treatment ( P<0.05). Patients with ATG treatment showed persistently higher levels of CD8(+)/CD57(+) double positive cells in the late postoperative phase ( P<0.05). In contrast, no differences could be observed between the two groups for major parameters of clinical outcome (acute rejections, severe infections, patient survival). We conclude that ATG therapy induces long-lasting alterations in T-cell subset composition. However, no beneficial clinical effect could be confirmed after liver transplantation.
机译:各种免疫抑制方案旨在降低肝移植后急性排斥反应的发生率。抗胸腺细胞球蛋白(ATG)诱导疗法的功效以及对细胞反应的短期影响已在多项研究中得到证实。但是,有关ATG治疗对细胞反应和并发症发生频率的长期影响的信息有限。因此,我们分析了基于环孢素的诱导疗法(包括硫唑嘌呤和泼尼松龙)中的ATG给药对淋巴细胞亚群和激活标记的影响。我们将35位肝移植受者根据其最初的术后免疫抑制分为两组:三组(无n = 15)和四组有ATG(n = 20)。最短观察时间(流式细胞仪分析,临床随访)为2年。接受ATG治疗的患者术后至少2年内T细胞百分比持续降低(P <0.001)。四倍组的CD4 / CD8比值较低(P <0.005)。 ATG组的患者显示2年内CD25(+)T细胞下降(P <0.05)。然而,接受ATG治疗的患者中CD71(+)和HLA-DR(+)T细胞的百分比暂时较高(P <0.05)。接受ATG治疗的患者在术后后期显示出持续较高水平的CD8(+)/ CD57(+)双阳性细胞(P <0.05)。相比之下,两组在临床结果的主要参数(急性排斥反应,严重感染,患者生存率)方面没有观察到差异。我们得出结论,ATG疗法可诱导T细胞亚群组成的长期改变。但是,肝移植后未确认有益的临床效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号